[1]梁 婷,斯 韬,刘湘慧,等.糖酵解及其关键限速酶在肝细胞癌中的作用研究进展[J].陕西医学杂志,2022,51(9):1171-1173.[doi:DOI:10.3969/j.issn.1000-7377.2022.09.030]
　LIANG Ting,SI Tao,LIU Xianghui,et al.Research progress of glycolysis and its key rate-limiting enzymes in liver cancer[J].,2022,51(9):1171-1173.[doi:DOI:10.3969/j.issn.1000-7377.2022.09.030]
点击复制

糖酵解及其关键限速酶在肝细胞癌中的作用研究进展
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
51
期数:
2022年9期
页码:
1171-1173
栏目:
综 述
出版日期:
2022-09-05

文章信息/Info

Title:
Research progress of glycolysis and its key rate-limiting enzymes in liver cancer
作者:
梁 婷1; 2; 斯 韬2; 刘湘慧1; 2; 覃正萍1; 2
(1.广西中医药大学,广西 南宁 530200; 2.广西中医药大学第三附属医院肿瘤科,广西 柳州 545001)
Author(s):
LIANG Ting; SI Tao; LIU Xianghui; QIN Zhengping
(Guangxi University of Traditional Chinese Medicine,Nanning 530200,China)
关键词:
肝细胞癌;  能量代谢;  糖酵解;  限速酶;  代谢重编程
Keywords:
Hepatocellular carcinoma;  Energy metabolism;  Glycolysis;  Rate-limiting enzyme;  Metabolic reprogramming
分类号:
R 735.7
DOI:
DOI:10.3969/j.issn.1000-7377.2022.09.030
文献标志码:
A
摘要:
肝细胞癌(HCC)患者往往生活质量不高,预后相对较差。我国作为HCC病例最多的国家,肝癌的治疗仍然是困扰流程工作者的难题。近年来肿瘤代谢重编程重新出现人们眼中,能量代谢包括脂质代谢、氨基酸代谢和糖酵解,而糖酵解则是能量代谢中提供能量的关键步骤,而其中的三种限速酶[己糖激酶(HK)、磷酸果糖激酶(PFK)和丙酮酸激酶(PK)]在HCC的发生与发展中具有重要作用。现对糖酵解及其关键限速酶在HCC中的作用进展进行综述,以期为HCC的靶向治疗和预后改善提供新的方向。
Abstract:
Patients with hepatocellular carcinoma(HCC)tend to have a poor quality of life and a relatively poor prognosis.As the country with the largest number of HCC cases in China,the treatment of liver cancer is still a difficult problem for clinical workers.In recent years,reprogramming of tumor metabolism reappears.Energy metabolism includes lipid metabolism,amino acid metabolism and glycolysis,and glycolysis is the key step in energy metabolism to provide energy.Among them,three rate-limiting enzymes [hexokinase(HK),phosphofructokinase(PFK)and pyruvate kinase(PK)] play an important role in the occurrence and development of HCC.This article reviews the progress of glycolysis and its key rate-limiting enzymes in HCC in order to provide new directions for targeted therapy and prognosis improvement of HCC.

参考文献/References:

[1] Mathupala S,Ko Y,Pedersen P.Hexokinase-2 bound to mitochondria:Cancer's stygian link to the “Warburg effect” and a pivotal target for effective therapy[J].Seminars in Cancer Biology,2009,19(1):17-24.
[2] Gatenby R,Gawlinski E.The glycolytic phenotype in carcinogenesis and tumor invasion:Insights through mathematical models[J].Cancer research,2003,63(14):3847-3854.
[3] Li S,Li J,Dai W,et al.Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death[J].British Journal of Cancer,2017,117(10):1518-1528.
[4] Xu Q,Tu J,Dou C,et al.HSP90 promotes cell glycolysis,proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma[J].Molecular cancer,2017,16(1):178.
[5] Xu Q,Dou C,Liu X,et al.Oviductus ranae protein hydrolysate(ORPH)inhibits the growth,metastasis and glycolysis of HCC by targeting miR-491-5p/PKM2 axis[J].Biomed Pharmacother,2018,107:1692-1704.
[6] Sheng T,Mao X,Zhang S.CaMKKβ regulates proliferation,apoptosis,and glycolysis of hepatocellular carcinoma via PI3K/AKT pathway[J].Annals of Palliative Medicine,2020,9(6):3857-3869.
[7] Kong J,Yu G,Si W,et al.Identification of a glycolysis-related gene signature for predicting prognosis in patients with hepatocellular carcinoma[J].BMC cancer,2022,22(1):142.
[8] Chen D,Ning W,Jiang Z,et al.Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma[J].Journal of Hepatology,2019,71(2):333-343.
[9] Peng Z,Jiang Z,Guo H,et al.Glycolytic activation of monocytes regulates the accumulation and function of neutrophils in human hepatocellular carcinoma[J].Journal of Hepatology,2020,73(4):906-917.
[10] Kumagai S,Koyama S,Itahashi K,et al.Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments[J].Cancer Cell,2022,40(2):201-218.
[11] Morrissey S,Zhang F,Ding C,et al.Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming[J].Cell Metabolism,2021,33(10):2040-2058.
[12] Liu W,Kang L,Han J,et al.MiR-342-3p suppresses hepatocellular carcinoma proliferation through inhibition of IGF-1R-mediated Warburg effect[J].Onco Targets and Therapy,2018,11:1643-1653.
[13] Gao H,Hao Y,Zhou X,et al.Prognostic value of glucose transporter 3 expression in hepatocellular carcinoma[J].Oncology Letters,2020,19(1):691-699.
[14] Patra K,Hay N.The pentose phosphate pathway and cancer[J].Trends in Biochemical Sciences,2014,39(8):347-354.
[15] Lis P,Dylag M,Niedzwiecka K,et al.The HK2 DEPENDENt “Warburg effect” and mitochondrial oxidative phosphorylation in cancer:Targets for effective therapy with 3-bromopyruvate[J].Molecules(Basel,Switzerland),2016,21(12):1730.
[16] Ciscato F,Ferrone L,Masgras I,et al.Hexokinase 2 in Cancer:A prima donna playing multiple characters[J].International Journal of Molecular Sciences,2021,22(9):4716.
[17] Dewaal D,Nogueira V,Terry A,et al.Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin[J].Nature Communications,2018,9(1):446.
[18] Wu Q,Wang S,Sun X,et al.Huachansu suppresses tumor growth and interferes with glucose metabolism in hepatocellular carcinoma cells by restraining Hexokinase-2[J].Int J Biochem Cell Biol,2022,142:106123.
[19] Anderson M,Marayati R,Moffitt R,et al.Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer[J].Oncotarget,2017,8(34):56081-56094.
[20] Chen P,Li J,Liu C,et al.Metabolic pathways enhancement confers poor prognosis in p53 exon mutant hepatocellular carcinoma[J].Cancer Informatics,2020,19:1176935119899913.
[21] Zhang C,Hu J,Sheng L,et al.Metformin delays AKT/c-met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation[J].Toxicology and Applied Pharmacology,2019,365:51-60.
[22] Al-Hasawi N,Alkandari M,Luqmani Y.Phosphofructokinase:A mediator of glycolytic flux in cancer progression[J].Critical Reviews in Oncology/Hematology,2014,92(3):312-321.
[23] Hu L,Zeng Z,Xia Q,et al.Metformin attenuates hepatoma cell proliferation by decreasing glycolytic flux through the HIF-1α/PFKFB3/PFK1 pathway[J].Life Sciences,2019,239:116966.
[24] Lee J,Liu R,Li J,et al.EGFR-phosphorylated platelet isoform of phosphofructokinase 1 promotes PI3K activation[J].Molecular Cell,2018,70(2):197-210.
[25] Houles T,Gravel S,Lavoie G,et al.RSK regulates PFK-2 activity to promote metabolic rewiring in melanoma[J].Cancer Research,2018,78(9):2191-2204.
[26] Chen Z,Lu X,Wang Z,et al.Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma[J].Oncotarget,2015,6(4):2538-2548.
[27] Wong N,Ojo D,Yan J,et al.PKM2 contributes to cancer metabolism[J].Cancer Letters,2015,356:184-191.
[28] Niekerk G,Engelbrecht A.Role of PKM2 in directing the metabolic fate of glucose in cancer:A potential therapeutic target[J].Cellular Oncology(Dordrecht),2018,41(4):343-351.
[29] 朱紫衣,刘晨霞,江忠勇,等.肿瘤细胞线粒体靶向治疗机制及药物研究进展[J].陕西医学杂志,2021,50(9):1170-1173.
[30] 武卫党,郭继文,张丹凤,等.五味子乙素改善糖酵解反应大鼠心肌缺血再灌注损伤实验研究[J].陕西医学杂志,2020,49(1):12-15.

相似文献/References:

[1]高延忠,王明利.CT联合MRI评估肝细胞癌病理分级可行性研究[J].陕西医学杂志,2022,51(3):375.[doi:DOI:10.3969/j.issn.1000-7377.2022.03.026]
[2]刘湘慧,斯 韬,梁 婷,等.铁死亡发生机制及其在肝细胞癌中的作用研究进展[J].陕西医学杂志,2023,52(3):354.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.025]
　LIU Xianghui,SI Tao,LIANG Ting,et al.Mechanism of ferroptosis and its role in hepatocellular carcinoma[J].,2023,52(9):354.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.025]
[3]黄丽银,斯 韬,梁 婷,等.丙酮酸脱氢酶激酶4在肝细胞癌中的作用研究进展[J].陕西医学杂志,2023,52(7):934.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.036]
　HUANG Liyin,SI Tao,LIANG Ting,et al.Research progress on role of pyruvate dehydrogenase kinase 4 in hepatocellular carcinoma[J].,2023,52(9):934.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.036]
[4]吴颖升,梁向娟,彭嘉敏,等.中性粒细胞外诱捕网在肝细胞癌转移中的作用机制及应用价值研究进展[J].陕西医学杂志,2024,(3):419.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.029]
　WU Yingsheng,LIANG Xiangjuan,PENG Jiamin,et al.Research progress on mechanism and application value of neutrophil extracellular traps in hepatocellular carcinoma metastasis[J].,2024,(9):419.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.029]
[5]张振奇,贺 莉.弥散加权成像联合动态对比增强磁共振成像在肝细胞肝癌患者肝动脉化疗栓塞术后肿瘤活性检测中的应用价值[J].陕西医学杂志,2024,(6):773.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.011]
　ZHANG Zhenqi,HE Li.Application value of DWI combined with DCE-MRI in detecting tumor activity in patients with hepatocellular carcinoma after TACE[J].,2024,(9):773.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.011]
[6]杨思瑜,曹春蕾,徐玉善,等.超声靶向微泡破坏技术在肝细胞癌基因治疗中的应用研究进展[J].陕西医学杂志,2024,(11):1567.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.028]
　YANG Siyu,CAO Chunlei,XU Yushan,et al.Research progress on the application of ultrasound-targeted microbubble destruction technology in gene therapy for hepatocellular carcinoma[J].,2024,(9):1567.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.028]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(82060856); 广西壮族自治区自然科学基金资助项目(2020JJA140194)
更新日期/Last Update: 2022-09-05